Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2024 03:00 ET | Source: HepaRegeniX GmbH

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regenerationElias Papatheodorou moves from Chair of the Board to CEO of...
July 09, 2024 20:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
July 09, 2024 16:53 ET | Source: Arcutis Biotherapeutics, Inc.

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis
July 09, 2024 16:45 ET | Source: Certara

Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio

Certara has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.
July 09, 2024 16:15 ET | Source: Nanobiotix S.A.

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 09 juill. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext...
July 09, 2024 16:15 ET | Source: Nanobiotix S.A.

Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, July 09,...
July 09, 2024 16:10 ET | Source: GENFIT S.A.

GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 9 juillet 2024 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans...
July 09, 2024 16:10 ET | Source: GENFIT S.A.

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
July 09, 2024 16:05 ET | Source: ImmuCell Corporation

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024

PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets...
July 09, 2024 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment...